Adebrelimab

Generic Name: Adebrelimab

Drug Type: Biotech

CAS Number: 2247114-85-6

Unique Ingredient Identifier: 1XBY50W1OX

Background: Adebrelimab is under investigation in clinical trial NCT03711305 (Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-stage (ES) Small Cell Lung Cancer (SCLC)).

Indication: 用于与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。

Clinical Trials

Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas

Phase 1

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: Adebrelimab
Drug: Dalpiciclib 100mg
Drug: Dalpiciclib 150mg

First Posted Date: 2024-01-26

Last Posted Date: 2024-03-06

Lead Sponsor: West China Hospital

Target Recruit Count: 6

Registration Number: NCT06225921

Locations: 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China

Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Phase 2

Recruiting

Conditions: Intrahepatic Cholangiocarcinoma

Interventions: Drug: Adebrelimab
Drug: Lenvatinib
Drug: Gemcitabine
Drug: Oxaliplatin

First Posted Date: 2024-01-17

Last Posted Date: 2025-03-03

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 33

Registration Number: NCT06208462

Locations: 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳
West China Hospital, Chengdu, Sichuan, China
🇨🇳
Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China

Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma

Phase 2

Not yet recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Adebrelimab and dalpiciclib

First Posted Date: 2024-01-10

Last Posted Date: 2024-01-22

Lead Sponsor: Zhongzheng Xiang

Target Recruit Count: 30

Registration Number: NCT06199271

Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Transformation Therapy for Locally Advanced Gastric Adenocarcinoma

Phase 4

Recruiting

Conditions: Locally Advanced Gastric Adenocarcinoma

Interventions: Drug: Placebo combined with SOX (S-1/oxaliplatin) regimen
Drug: Adebrelimab combined with SOX regimen

First Posted Date: 2024-01-05

Last Posted Date: 2024-01-29

Lead Sponsor: Yang Jianjun, PhD

Target Recruit Count: 110

Registration Number: NCT06192186

Locations: 🇨🇳
The First Affiliated Hospital of the Air Force Medical University, Xi'an, China

Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy

Phase 2

Not yet recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Adebrelimab Combined with Bevacizumab and Docetaxel

First Posted Date: 2023-12-27

Last Posted Date: 2023-12-27

Lead Sponsor: The First Affiliated Hospital of Xinxiang Medical College

Target Recruit Count: 35

Registration Number: NCT06182800

A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies

Phase 1

Recruiting

Conditions: Biliary Tract Malignancies

Interventions: Drug: Adebrelimab
Drug: Apatinib
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2023-12-26

Last Posted Date: 2024-04-30

Lead Sponsor: First Affiliated Hospital of Fujian Medical University

Target Recruit Count: 35

Registration Number: NCT06181032

Locations: 🇨🇳
The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial

Phase 2

Not yet recruiting

Conditions: Esophageal Squamous Cell Carcinoma

First Posted Date: 2023-12-20

Last Posted Date: 2023-12-20

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 36

Registration Number: NCT06178211

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, China

Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

Phase 2

Recruiting

Conditions: Pancreatic Cancer
Neoadjuvant Therapy

Interventions: Drug: Adebrelimab
Drug: albumin-bound paclitaxel
Drug: Gemcitabine

First Posted Date: 2023-12-20

Last Posted Date: 2024-08-16

Lead Sponsor: Jinling Hospital, China

Target Recruit Count: 30

Registration Number: NCT06177522

Locations: 🇨🇳
Wang Sizhen, Nanjing, Jiangsu, China

A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC

Phase 2

Recruiting

Conditions: Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Small Cell Lung Carcinoma
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms

Interventions: Drug: Adebrelimab
Drug: Carboplatin/Cisplatin
Drug: Etoposide
Radiation: Radiation therapy

First Posted Date: 2023-12-20

Last Posted Date: 2023-12-20

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 62

Registration Number: NCT06177925

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, China

Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC

Phase 2

Recruiting

Conditions: Stereotactic Radiotherapy
Immunotherapy
Breast Cancer

Interventions: Drug: adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)
Drug: adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)

First Posted Date: 2023-12-12

Last Posted Date: 2024-01-03

Lead Sponsor: Shengjing Hospital

Target Recruit Count: 136

Registration Number: NCT06165900

Locations: 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy